Diabetes is a metabolic disorder in which the body glucose level is
elevated. Gestational diabetes is a temporary or permanent form of diabetes in
which the body does not produce adequate amounts of insulin to regulate sugar
during pregnancy. It may also be called glucose intolerance or carbohydrate
intolerance. According to the International Diabetes Federation in 2016, it
was estimated that 420 million adult population is suffering from diabetes
which is increasing at the rate of 8.4% and is expected to reach 625 million by
2040. According to the American Pregnancy Association, approximately 2-5% of
pregnant women develop gestational diabetes; this number may increase to 7-9%
of mothers who are more likely to have risk factors. Increasing prevalence of
the gestational diabetic population is the major driving factor for the growth
of the market. Moreover, increasing obese population, increasing healthcare
expenditure, and strong encouragement from the government have also contributed
to the growth of the market. According to research, smoking increases the
possibility of diabetes; more than 60% of the global population smokes, this
has increased the risk of diabetes and contributed to the growth of the market.
However, lack of awareness among people and cost issues may lead to restrain
the growth of the market.
Browse
Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4591
The global
gestational diabetic market is expected to grow at a CAGR of 5.4% during
forecast period.
Segmentation
The global gestational diabetes market is segmented on the basis of
types, administration, treatment, and end users.
On the basis of types, the market is segmented into type A1, type A2 and
others.
On the basis of administration, the market is categorised into oral,
intravenous, and other.
On the basis of treatment, the market is segmented into monitoring, drug
treatment, and non-pharmacological treatment. Monitoring is further segmented
into urinary glucose testing, oral glucose tolerance test, and others. Drug
treatment is subsegmented into insulin, sensitizers, SGLT-2 inhibitors,
alpha-glucosidase inhibitors, and others
On the basis of end users, the market is segmented into hospital, retail
pharmacy and other.
Regional
Analysis
America dominates the global gestational diabetes market owing to large
patient population. Apart from this, increasing number of obese people,
changing lifestyle and increasing healthcare expenditure have boosted the
growth of the market in America. According to the Centers for Disease Control
and Prevention (2014), 73.5 million adults in the US were diagnosed with high
cholesterol level. Increasing cholesterol level and smoking increases the
possibility of causing diabetes. Additionally, increasing awareness among the
people regarding different monitoring procedures and well-developed technology
has also contributed to the growth of the market.
Europe is the second largest gestational diabetes market, which is
followed by Asia Pacific. Huge smoking population, availability of funds for
research, and government support for research & development will drive the
market.
Asia Pacific is the fastest growing region for the market due to the
presence of a huge patient population, continuously developing economies, and
increasing need for the better treatment.
On the other hand, the Middle East & Africa has the least share in the
global gestational diabetes market due to presence of poor economy especially
in Africa region. Majority of the market of this region is hold by Middle East
due to well-developed healthcare sector and huge healthcare expenditure.
Key players for global gestational diabetes market
Antares Pharma (US), INJEX Pharma AG (Germany), 3M (US), Eli Lilly (US),
Biocon (US), Sunpharma (India), Sanofi (France), Novo Nordisk (Denmark), Abbott
(US), AstraZeneca (UK), Novartis (Switzerland), Daiichi Sankyo (Japan),
Boehringer Ingelheim (Germany), Merck & Co. (US), Pfizer (US), Akros Pharma
(US), Amgen (US), Adocia (France), Peptron (South Korea), and Takeda (Japan).
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/gestational-diabetes-market-4591
About US:
Market Research Future (MRFR), enable customers to unravel the
complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
No comments:
Post a Comment